← Evolus, Inc.
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue: | $0 | $34.9m | $56.5m | $99.7m | $148.6m | $202.1m | $266.3m | $297.2m | $316.5m | |
| Cost of goods sold | $0 | $8.0m |
$18.3m
+128.34%
|
$43.5m
+137.90%
|
$55.9m
+28.38%
|
$61.6m
+10.15%
|
$84.0m
+36.41%
|
$100.1m
+19.17%
|
$105.3m
+5.21%
|
|
| Gross profit (derived) | $0 | $26.9m |
$38.2m
+42.10%
|
$56.1m
+46.80%
|
$89.8m
+59.91%
|
$137.6m
+53.24%
|
$182.3m
+32.52%
|
$197.1m
+8.12%
|
$211.2m
+7.15%
|
|
| Research and development | $6.5m | $4.0m | $1.7m | $2.1m | $4.7m | $6.6m | $9.2m | $9.6m | $9.7m | |
| In-process research and development | — | — | — | $0 | $2.0m | $8.9m | $0 | $0 | — | |
| Selling, general and administrative | $29.1m | $113.6m | $98.2m | $112.1m | $141.8m | $164.9m | $198.0m | $220.8m | $216.5m | |
| Restructuring costs | — | $0 | $3.0m | $0 | — | $0 | $0 | $1.4m | — | |
| Total operating expenses | $46.1m | $125.9m | $209.6m | $144.1m | $213.9m | $251.3m | $216.7m | $229.8m | $231.8m | |
| Loss from operations | ($46.1m) |
($98.9m)
-114.44%
|
($153.1m)
-54.70%
|
($44.4m)
+70.99%
|
($65.3m)
-47.12%
|
($49.2m)
+24.64%
|
($34.4m)
+30.11%
|
($32.7m)
+5.08%
|
— | |
| Interest expense | $863k | — | — | ($1.4m) | ($9.1m) | ($13.8m) | ($18.7m) | ($19.7m) | $16.2m | |
| Interest income | $203k | $1.8m | $635k | $1k | $119k | $860k | $3.3m | $1.9m | $1.3m | |
| Other income (expense), net | ($863k) | ($8.0m) | ($10.5m) | ($1.4m) | ($9k) | $696k | $127k | ($539k) | $1.8m | |
| Loss before income taxes | ($46.8m) | ($105.1m) | ($162.9m) | ($46.8m) | ($74.3m) | ($61.5m) | ($49.8m) | ($51.0m) | — | |
| Income tax expense | $65k | ($15.0m) | $77k | $42k | $95k | $176k | $664k | ($677k) | $654k | |
| Net loss | ($46.9m) | ($90.0m) | ($163.0m) | ($46.8m) | ($74.4m) | ($61.7m) | ($50.4m) | ($51.6m) | — | |
| Net loss per share, basic (in dollars per share) | — | — | ($5) | ($1) | ($1) | ($1) | ($1) | ($1) | — | |
| Net loss per share, diluted (in dollars per share) | — | — | ($5) | ($1) | ($1) | ($1) | ($1) | ($1) | — | |
| Weighted-average shares outstanding used to compute basic net loss per share (in shares) | — | — | (5) | (1) | (1) | (1) | (1) | (1) | — | |
| Weighted-average shares outstanding used to compute diluted net loss per share (in shares) | — | — | (5) | (1) | (1) | (1) | (1) | (1) | — | |
| Revaluation of contingent royalty obligation payable to Evolus Founders | — | $4.2m | ($2.0m) | $6.3m | $5.8m | ($4.3m) | $7.2m | ($6.4m) | — | |
| Depreciation and amortization | $9k | $4.1m | $7.0m | $5.6m | $3.7m | $5.1m | $2.3m | $4.3m | $5.7m | |
| Currency translation adjustment | — | — | — | — | — | ($90k) | ($478k) | $749k | — | |
| Comprehensive loss | ($46.9m) | ($90.0m) | ($163.0m) | ($46.8m) | ($74.7m) | ($61.8m) | ($50.9m) | ($50.9m) | — |